Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.365 USD | -3.19% | -12.50% | -48.30% |
08/04 | Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024 | |
08/04 | North American Morning Briefing : Inflation Data, -2- | DJ |
Sales 2024 * | 9.01M 751M | Sales 2025 * | 15.73M 1.31B | Capitalization | 66.4M 5.54B |
---|---|---|---|---|---|
Net income 2024 * | -57M -4.75B | Net income 2025 * | -68M -5.67B | EV / Sales 2024 * | 7.37 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.22 x |
P/E ratio 2024 * |
-1.32
x | P/E ratio 2025 * |
-1.36
x | Employees | 53 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.03% |
Latest transcript on Cue Biopharma, Inc.
1 day | -3.19% | ||
1 week | -12.50% | ||
Current month | -27.78% | ||
1 month | -25.82% | ||
3 months | -48.30% | ||
6 months | -23.74% | ||
Current year | -48.30% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel Passeri
CEO | Chief Executive Officer | 63 | 01/16/01 |
Anish Suri
PSD | President | 50 | 01/18/01 |
Kerri-Ann Millar
DFI | Director of Finance/CFO | 54 | 01/17/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 74 | 26/18/26 |
Daniel Passeri
CEO | Chief Executive Officer | 63 | 01/16/01 |
Peter Kiener
BRD | Director/Board Member | 72 | 01/16/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 2 M€ | -.--% | ||
0.00% | 34 M€ | +2.14% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 1.365 | -3.19% | 264,389 |
25/24/25 | 1.41 | -0.70% | 169,155 |
24/24/24 | 1.42 | -5.33% | 319,520 |
23/24/23 | 1.5 | -4.46% | 161,467 |
22/24/22 | 1.57 | +0.64% | 181,253 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-48.30% | 66.4M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- CUE Stock